RTP Mobile Logo
RTP TV: Part II — Melanoma: Novel Pathways and Agents
Released June 2011

The second seminar of our eight-part online, integrated educational course on issues relevant to the current and future treatment of several different solid tumors and hematologic cancers features Drs Keith T Flaherty, Adriano Piris and Jeffrey Weber. Part II (originally held June 21, 2011) features discussion of the latest clinical research data sets in melanoma. (Webinar)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of melanoma.

    OVERVIEW OF ACTIVITY

    Between the 1960s and the 1990s, the incidence of melanoma and the mortality rates associated with this disease rose precipitously in most developed and industrialized nations around the world. Despite increased awareness of this phenomenon and extensive attempts to publicize risk factors and screening, current estimates suggest that 68,130 men and women were diagnosed with melanoma and 8,700 individuals died from the disease in 2010 within the United States alone.

    Although most patients with in situ or early-stage melanoma may be cured by primary excision in the absence of systemic therapy, the prognosis of patients with metastatic melanoma remains poor. The disappointing impact of existing interventions on clinical outcomes in Stage IV disease has resulted in a need to continue to investigate novel treatment options for patients. Novel treatments exploiting the biologic and genomic characteristics of melanomatous tumors have made this disease a fertile ground for application of emerging systemic therapeutics.

    This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A, discussion of community practice patterns and a melanoma pathology tutorial to assist practicing clinicians with the incorporation of investigational findings from the multitude of diverse ongoing trials into routine clinical care.

    LEARNING OBJECTIVES

    • Use case-based learning to individualize the care of patients with metastatic melanoma.
    • Communicate the benefits and risks of ipilimumab-based therapy to appropriately selected patients with advanced-stage melanoma.
    • Recall emerging data with BRAF inhibitors in the targeted treatment of melanoma, and identify how these agents may affect diagnosis and management of the disease.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity consists of two video components. The participant should watch the videos.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Keith T Flaherty, MD

    Associate Professor, Harvard Medical School
    Director of Developmental Therapeutics
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology; Consulting Agreements: Cephalon Inc, GlaxoSmithKline.

    Adriano Piris, MD
    Dermatopathologist, Massachusetts General Hospital
    Director, Quality and Safety Division, MGH Dermatopathology
    Instructor of Pathology, Harvard Medical School
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    Jeffrey Weber, MD, PhD

    Senior Member, H Lee Moffitt Cancer Center
    Director, Donald A Adam Comprehensive Melanoma Research Center
    Tampa, Florida

    Advisory Committee: Bristol-Myers Squibb Company, Celldex Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation; Consulting Agreement: Bristol-Myers Squibb Company; Stock Ownership: Celldex Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Bristol-Myers Squibb Company and Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio 

    Last review date
    : June 2011
    Expiration date: June 2012

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):
Watch Pathology of Primary Melanoma Video